The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Akhmedova A.A.

Pirogov Russian National Research Medical University (Pirogov University)

Ushanova F.O.

Pirogov Russian National Research Medical University (Pirogov University)

Demidova T.Yu.

Pirogov Russian National Research Medical University (Pirogov University)

Cognitive functions assessment of elderly patients with type 2 diabetes mellitus

Authors:

Akhmedova A.A., Ushanova F.O., Demidova T.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3): 46‑50

DOI: 10.17116/jnevro202512503146

Read: 867 times

Buy for 300₽
Contact the author
Table of contents

COGNITIVE FUNCTIONS ASSESSMENT OF ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS
COGNITIVE FUNCTIONS ASSESSMENT OF ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS

To cite this article:

Akhmedova AA, Ushanova FO, Demidova TYu. Cognitive functions assessment of elderly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3):46‑50. (In Russ.)
https://doi.org/10.17116/jnevro202512503146

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

OBJECTIVE

Comparative assessment of the cognitive status of persons over 60, depending on the presence or absence of type 2 diabetes mellitus (T2DM).

MATERIAL AND METHODS

The study included 193 patients, of which 93 had no T2DM and 100 had T2DM. The mean age of patients with T2DM was 73 [68; 78] years vs. 69.2 [64; 75] years in patients without T2DM. The cognitive function was assessed using the McNair and Kahn scale, with scores over 42 indicating cognitive dysfunction and Kahn scale: in the group with T2DM, the average score was 27.0±9.36; in the group without T2DM, it was 22.0±9.60 (p<0.043). The absence of T2DM was negatively correlated with the total score on the scale for assessing the risk of cognitive impairment (p=–0.264, p<0.001). In addition, it was found that age over 75 years was significantly associated with the development of cognitive impairment, regardless of the presence of concomitant T2DM (OR=1.247, CI=95%, 1.112—1.40, p<0.001).

CONCLUSION

T2DM increases the risk of developing cognitive dysfunction, which should be taken into account in older patients for the timely detection and prevention of its progression.

Keywords:

diabetes mellitus
cognitive dysfunction
cognitive disorders

Authors:

Akhmedova A.A.

Pirogov Russian National Research Medical University (Pirogov University)

Ushanova F.O.

Pirogov Russian National Research Medical University (Pirogov University)

Demidova T.Yu.

Pirogov Russian National Research Medical University (Pirogov University)

Received:

26.09.2024

Accepted:

10.10.2024

Close metadata

References:

  1. Dementia. Fact sheet N362. March 2015. https://www.who.int/mediacentre/factsheets/fs362/en/
  2. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74.  https://doi.org/10.1016/S1474-4422(05)70284-2
  3. Wong RH, Scholey A, Howe PR. Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus--a review with implications for future intervention studies. Curr Diab Rep. 2014;14(11):547.  https://doi.org/10.1007/s11892-014-0547-4
  4. Sachdev PS, Lipnicki DM, Kochan NA, et al. The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS One. 2015;10(11):e0142388. https://doi.org/10.1371/journal.pone.0142388
  5. Chatterjee S, Peters SA, Woodward M, et al. Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care. 2016;39(2):300-307.  https://doi.org/10.2337/dc15-1588
  6. Zilliox LA, Chadrasekaran K, Kwan JY, et al. Diabetes and Cognitive Impairment. Curr Diab Rep. 2016;16(9):87.  https://doi.org/10.1007/s11892-016-0775-x
  7. Gaspar JM, Baptista FI, Macedo MP, et al. Inside the Diabetic Brain: Role of Different Players Involved in Cognitive Decline. ACS Chem Neurosci. 2016;7(2):131-142.  https://doi.org/10.1021/acschemneuro.5b00240
  8. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci. 2008;9(1):36-45.  https://doi.org/10.1038/nrn2294
  9. Nuckols CC. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Philadelphia: American Psychiatric Association. 2013.
  10. Benarroch EE. NMDA receptors: recent insights and clinical correlations. Neurology. 2011;76(20):1750-1757. https://doi.org/10.1212/WNL.0b013e31821b7cc9
  11. Skeberdis VA, Lan J, Zheng X, et al. Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci USA. 2001;98(6):3561-3566.
  12. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(1):35-66.  https://doi.org/10.2174/156720512799015037
  13. Calvo-Ochoa E, Arias C. Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer’s disease: studies in animal models. Diabetes Metab Res Rev. 2015;31(1):1-13.  https://doi.org/10.1002/dmrr.2531
  14. Golpich M, Amini E, Hemmati F, et al. Glycogen synthase kinase-3 β (GSK-3β) signaling: implications for Parkinson’s disease. Pharmacol Res. 2015;97:16-26.  https://doi.org/10.1016/j.pharmthera.2014.11.016
  15. Nagao M, Hayashi H. Glycogen synthase kinase-3β is associated with Parkinson’s disease. Neurosci Lett. 2009;449:103-107.  https://doi.org/10.1016/j.neulet.2008.10.104
  16. Su B, Wang X, Zheng L, et al. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta. 2010;1802(1):135-142.  https://doi.org/10.1016/j.bbadis.2009.09.013
  17. Ostroumova OD, Surkova EV, Chikh EV, et al. Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs. Diabetes mellitus. 2018;21(4):307-318. (In Russ.). https://doi.org/10.14341/DM9660
  18. Cognitive disorders in elderly and senile patients. Clinical recommendations of the Ministry of Health of the Russian Federation. Year of approval: 2020. (In Russ.).
  19. Breton A, Casey D, Arnaoutoglou NA. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry. 2019;34(2):233-242.  https://doi.org/10.1002/gps.5016
  20. Belleville S, Fouquet C, Hudon C, et al. Neuropsychological Measures that Predict Progression from Mild Cognitive Impairment to Alzheimer’s type dementia in Older Adults: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2017;27:328-353.  https://doi.org/10.1007/s11065-017-9361-5
  21. Dardenne S, Delrieu J, Sourdet S, et al. Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. J Alzheimers Dis. 2017;60(4):1567-1578.
  22. Kravitz E, Schmeidler J, Schnaider Beeri M. Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies. Endocrinol Metab Clin North Am. 2013;42(3):489-501.  https://doi.org/10.1016/j.ecl.2013.05.009
  23. Dye L, Boyle NB, Champ C, et al. The relationship between obesity and cognitive health and decline. Proc Nutr Soc. 2017;76(4):443-454.  https://doi.org/10.1017/S0029665117002014
  24. Fiatarone Singh MA, Gates N, Saigal N, et al. The Study of Mental and Resistance Training (SMART) study—resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. J Am Med Dir Assoc. 2014;15(12):873-880.  https://doi.org/10.1016/j.jamda.2014.09.010
  25. Valente T, Gella A, Fernàndez-Busquets X, et al. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis. 2010;37(1):67-76.  https://doi.org/10.1016/j.nbd.2009.09.008
  26. Launer LJ, Miller ME, Williamson JD, et al. ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969-977.  https://doi.org/10.1016/S1474-4422(11)70188-0
  27. Shemesh E, Rudich A, Harman-Boehm I, et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012;97(2):366-376.  https://doi.org/10.1210/jc.2011-1802
  28. Morris JK, Vidoni ED, Mahnken JD, et al. Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. Neurobiol Aging. 2016;39:19-24.  https://doi.org/10.1016/j.neurobiolaging.2015.11.005
  29. Erus G, Battapady H, Zhang T, et al. Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose. Diabetes Care. 2015;38(1):97-104.  https://doi.org/10.2337/dc14-1196
  30. Hanyu H, Sato T, Kiuchi A, et al. Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009;57(1):177-179.  https://doi.org/10.1111/j.1532-5415.2009.02067.x
  31. Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm. 2010;84:331-354.  https://doi.org/10.1016/B978-0-12-381517-0.00013-8
  32. Abbatecola AM, Lattanzio F, Molinari AM, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706-1711. https://doi.org/10.2337/dc09-2030
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.